A study of adjuvant STATin therapy in the prevention of postoperative Recurrence of Oesophageal adenoCarcinoma (The STATROC study).
Despite the current standard of care for patients on a curative pathway with invasive oesophageal adenocarcinoma (OAC), risk of future cancer recurrence and mortality remains high. Currently there are no longer-term treatments after curative surgery to prevent cancer recurrence and improve survival. There is strong observational evidence to suggest that statins, commonly used for the prevention of cardiovascular disease, are associated with improved all-cause and cancer-specific survival. Experimental evidence suggests that statins could play a role in slowing the rate of growth of cancer cells, cancer cell death and in limiting their metastatic spread. The STAT-ROC (STATins for the prevention of Recurrence of Oesophageal adenoCarcinoma) trial is a national collaboration of 25 major oesophago-gastric centres, led by Norwich Medical School and the Norfolk and Norwich University Hospital’s gastroenterology and surgical departments (CI Prof Andrew Hart). The trial aims to investigate whether adjuvant statin therapy improves survival and reduces recurrence in patients with operable OAC. In October 2016 the group completed a successful NIHR-funded multicentre randomised controlled feasibility trial of adjuvant statin therapy (the STAT-ROC feasibility trial). This demonstrated the feasibility of the future planned phase III trial and informed its design and conduct. The group plan to submit an application for competitive funding this year.